Avidity Biosciences Inc
RNAM
Peringkat dalam Saham
#2069
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Harga Saham
$71.34
Terakhir disinkronkan: 2026-03-03
Kapitalisasi Pasar
$9.84B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-
Negara
US
Perdagangan Avidity Biosciences Inc (RNAM)
Kategori
Healthcare
Jumlah saham beredar untuk Avidity Biosciences Inc (RNAM)
Jumlah saham beredar per October 2026: 0
Menurut laporan keuangan terbaru dan harga saham Avidity Biosciences Inc, jumlah saham beredar saat ini adalah 0. Pada akhir October 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Avidity Biosciences Inc (RNAM) dari 2018 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2025 | 137.71M | 23.42% |
| 2024 | 111.58M | 52.83% |
| 2023 | 73.01M | 39.97% |
| 2022 | 52.16M | 25.91% |
| 2021 | 41.43M | 91.24% |
| 2020 | 21.66M | -42.27% |
| 2019 | 37.53M | 0.04% |
| 2018 | 37.51M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 0.00 | - |
BE
|
|
| 62.19M | - |
NL
|
